Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (GB:0QOK)
LSE:0QOK
Roche Holding AG (0QOK) Share Price & Analysis
24 Followers
0QOK Stock Chart & Stats
Day’s RangeCHF0 - CHF0
52-Week RangeCHF213.90 - CHF286.51
Previous CloseCHF229.56
Volume553.67K
Average Volume (3M)965.86K
Market Cap
CHF186.04B
Enterprise ValueCHF207.75B
Total Cash (Recent Filing)CHF7.51B
Total Debt (Recent Filing)CHF25.39B
Price to Earnings (P/E)16.0
Beta0.51
Next Earnings
Jul 25, 2024EPS Estimate
CHF9.24Next Dividend Ex-DateN/A
Dividend Yield4.32%
Share Statistics
EPS (TTM)14.40
Shares Outstanding800,578,845
10 Day Avg. Volume54,796
30 Day Avg. Volume965,861
Standard Deviation0.05
R-Squared0.04
Alpha0.00008
Financial Highlights & Ratios
Price to Book (P/B)93.14
Price to Sales (P/S)2.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF246.85Price Target Upside7.53% Upside
Rating ConsensusHold
Number of Analyst Covering10
Roche Holding AG News
![[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19](https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1917115745-750x406.jpg)
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentGYM329's promising pharmacodynamics profile suggests a competitive edge, with the potential for lower dosages and addressing manufacturing and cost concerns.
Product SalesActemra sales outperform expectations significantly, signaling strong market demand and competitive advantage ahead of biosimilar entries.
Strategic AcquisitionRoche's strategic acquisition enhances its market position by adding a unique and potent incretin portfolio, potentially leading to increased market share.
Bears Say
Earnings Miss4Q23 group sales missed consensus estimates by 2%.
Product PerformanceKey products Hemlibra and Ocrevus missed expectations by 6% and 2%, respectively.
Profit Miss And Growth ConcernsMid-single-digit growth guidance for 2024 suggests downside to consensus sales and EPS.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
19.37% Mutual Funds
8.85% Other Institutional Investors
71.77% Public Companies and
Individual Investors
0QOK FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest share price was CHF213.90 and its highest was CHF286.51 in the past 12 months.
What is Roche Holding AG’s market cap?
Currently, no data Available
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 25, 2024 which is in 91 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Feb 01, 2024. The company reported CHF8.47 earnings per share for the quarter, beating the consensus estimate of CHF8.37 by CHF0.1.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG does not currently pay dividends.
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is CHF9.24.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF8.47 in its last earnings report, beating expectations of CHF8.37. Following the earnings report the stock price went down -4.398%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in GB:0QOK
---
Roche Holding AG Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF246.85 (7.53% Upside)
CHF246.85 (7.53% Upside)
Blogger Sentiment
Bullish
GB:0QOK Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.63%
12-Months-Change
Fundamentals
Return on Equity
39.18%
Trailing 12-Months
Asset Growth
12.82%
Trailing 12-Months
Company Description
Roche Holding AG
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
---
0QOK Company Deck
---
0QOK Earnings Call
Q4 2024
0:00 / 0:00
---
0QOK Stock 12 Months Forecast
Average Price Target
CHF246.85
▲(7.53% Upside)
Technical Analysis
Best Analysts Covering 0QOK
1 Year
1 Year Success Rate
33/36 ratings generated profit
1 Year Average Return
+13.38%
reiterated a sell rating 13 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +13.38% per trade.
---